WASHINGTON — The president’s call to split the combined measles, mumps and rubella vaccine into three separate shots has already attracted the one constituency genetically incapable of leaving a functional bundle alone: startup founders. NeedleStack, a fictional health-tech venture, announced Monday that it is developing “MMR-as-a-Service,” a platform designed to convert one established pediatric product into three à la carte clinical SKUs.
Doctors and vaccine experts say there is no scientific basis for separating the MMR vaccine, and that such a change is unlikely to happen. Producing individual shots would require manufacturers to alter supply lines, seek appropriate regulatory licensing and somehow improve upon the current logistical breakthrough known as “doing one thing once.” Children would also face more needle sticks and potentially more visits.
NeedleStack views those obstacles as a total addressable market. “Healthcare keeps asking how to reduce friction, which is exactly why nobody has monetised the friction,” said Trey Basispoint, the company’s fictional chief unbundling officer. “One injection is a legacy monolith. Three injections are microservices with recurring touchpoints.”
“One injection is a legacy monolith. Three injections are microservices with recurring touchpoints.”
The proposed product suite would divide the familiar vaccine into three branded tiers: Measles Core, Mumps Plus and Rubella Pro. Families would not receive medical benefits from this pricing architecture, because it is not a real medical proposal. They would, however, experience what NeedleStack calls “choice-forward needle optionality,” a phrase engineered to make additional scheduling sound like airport lounge access.
